| [1] |
Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. |
| [2] |
CORNBERG M, SANDMANN L, PROTZER U, et al. S3-Leitlinie der deutschen gesellschaft für gastroenterologie, verdauungs-und stoffwechselkrankheiten (DGVS) zur prophylaxe, diagnostik und therapie der hepatitis-B-virusinfektion-(AWMF-Register-Nr. 021-11)[J]. Z Gastroenterol, 2021, 59(7): 691-776. DOI: 10.1055/a-1498-2512. |
| [3] |
CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311. |
| [4] |
GUI HL, WANG H, YANG YH, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase[J]. J Viral Hepat, 2010, 17(Suppl 1): 44-50. DOI: 10.1111/j.1365-2893.2010.01270.x. |
| [5] |
KIM JH, SINN DH, KANG W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343. DOI: 10.1002/hep.28916. |
| [6] |
FAN YX, DOU XG. Optimal timing significance and clinical implications for the treatment of chronic HBV-infected patients with normal ALT[J]. Chin J Hepatol, 2020, 28(11): 170-172. DOI: 10.3760/cma.j.cn501113-20201026-00579. |
| [7] |
CHU CM, LIAW YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus[J]. Am J Gastroenterol, 2009, 104(7): 1693-1699. DOI: 10.1038/ajg.2009.187. |
| [8] |
HAN C, DOU XG. Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: Consensus and contention[J]. Chin J Hepatol, 2021, 4(29): 192-195. DOI: 10.3760/cma.j.cn501113-20210326-00139. |
| [9] |
FANNING GC, ZOULIM F, HOU J, et al. Therapeutic strategies for hepatitis B virus infection: Towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11): 827-844. DOI: 10.1038/s41573-019-0037-0. |
DownLoad: